2016 Fiscal Year Final Research Report
Increased soluble CD155 in the serum of cancer patients
| Project/Area Number |
16K14629
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2016-04-01 – 2017-03-31
|
| Keywords | 免疫系受容体 / 腫瘍マーカー |
|---|
| Outline of Final Research Achievements |
DNAM-1 plays an important role in the recognition of tumor cells and their lysis by CTL and NK cells. Although the DNAM-1 ligand CD155 is ubiquitously expressed in various tissues, many tumors significantly upregulate the expression of CD155. We demonstrated that the interaction of DNAM-1 on CTL and NK cells and CD155 on tumors was involved in mouse tumor immunity. However, unlike those in mice, human tissues also express soluble isoforms of CD155 (sCD155) that lack the transmembrane region. Here, we show that sCD155 levels were significantly higher in the sera of patients with cancers than in sera from healthy donors. In addition, the sCD155 levels were significantly higher in patients with advanced stage disease than in patients in those with early stage disease. Moreover, the sCD155 levels were significantly decreased after surgical resection of cancers. Thus, sCD155 level in serum may be potentially useful as a biomarker for cancer development and progression.
|
| Free Research Field |
免疫学
|
